PPARδ inhibition blocks the induction and function of tumor-induced IL-10⁺ regulatory B cells and enhances cancer immunotherapy.

ABSTRACT: IL-10⁺ regulatory B cells (Bregs) play a significant role in cancer immunotherapy and their presence is an indicator of negative outcome. We found that PPARδ is significantly upregulated in tumor-induced IL-10⁺ Bregs with a phenotype of CD19⁺CD24^hiIgD^lo/-CD38^lo or CD19⁺CD24^hiIgD^lo/-CD38^hi in both mice and humans, and the level of PPARδ expression was correlated with their potential to produce IL-10 and to inhibit T cell activation. Genetic inactivation of PPARδ in B cells impaired the development and function of IL-10⁺ B cells, and treatment with PPARδ inhibitor diminished the induction of IL-10⁺ Bregs by tumor and CD40 engagement. Importantly, immunotherapy w

SUBMITTER: Chen C 

PROVIDER: S-EPMC10250529 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature